Chimeric antigen receptor (CAR)‐T therapy has emerged as a promising cell‐based immunotherapy approach for treating blood disorders and cancers, but genetically engineering CAR‐T cells is challenging due to primary T cells’ sensitivity to conventional gene delivery approaches. The current viral‐based method can typically involve significant operating costs and biosafety hurdles, while bulk electroporation can lead to poor cell viability and functionality. Here, we develop a non‐viral electroactive nanoinjection (ENI) platform to efficiently negotiate the plasma membrane of primary human T cells via vertically configured electroactive nanotubes, enabling efficient delivery (68.7%) and expression (43.3%) of CAR genes in the T cells, with minimal cellular perturbation (> 90% cell viability). Compared to conventional bulk electroporation (BEP), the ENI platform achieves an almost 3‐fold higher CAR transfection efficiency, indicated by the significantly higher reporter GFP expression (43.3% compared to 16.3%). By co‐culturing with target lymphoma Raji cells, we prove the ENI‐transfected CAR‐T cells’ ability to effectively suppress lymphoma cell growth (86.9% cytotoxicity). Taken together, the results demonstrate the platform's remarkable capacity to generate functional and effective anti‐lymphoma CAR‐T cells. Given the growing potential of cell‐based immunotherapies, we anticipate that a non‐viral and efficient nanoinjection platform like the one described here will offer a promising avenue for ex vivo cell engineering, particularly in the context of CAR‐T cell therapy.This article is protected by copyright. All rights reserved